
Biohaven Ltd. (BHVN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BIOHAVEN LTD. (BHVN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors.
Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]' On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025.
Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025. On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025.
Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further.
Contact Us To Participate or Learn More:
If you purchased Biohaven securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
What to Watch Ahead of Disney Q3 Earnings
Disney (NYSE:DIS) reports third-quarter results for fiscal 2025 before the market opens on August 6. Consensus estimates call for adjusted EPS of approximately $1.45 on revenue of $23.7 billion, implying modest 2% top-line growth YoY. The stock is up 4% year-to-date and trades roughly 7% below its 52-week high of $124.70. Investor attention will focus on direct-to-consumer (DTC) margins and subscriber momentum. In Q2, Disney's DTC segment generated $336 million in operating income, up from $47 million a year earlier and added 1.4 million Disney+ subscribers. Subscriber stability and continued margin expansion will be key focus areas, as investors assess whether Disney's cost discipline is translating into lasting DTC profitability. The Experiences segment (theme parks and cruises) continues to perform well. Q2 experiences operating income rose 8% YoY to $2.5 billion, with investors assessing whether gating capacity or rising costs could pressure margins in Q3. Investors may also listen for commentary on recent releases such as Snow White and Fantastic Four, as sentiment around Disney's film strategy has been mixed and studio margins remain under pressure. With forward guidance unchanged ($5.75 adjusted EPS full year) and streaming margins expected to contribute more in H2, Disney's Q3 commentary will be critical. Management will need to demonstrate both streaming discipline and theme park profitability to support the current valuation. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Pitney Bowes Inc. (PBI): A Bull Case Theory: A Bull Case Theory
We came across a bullish thesis on Pitney Bowes Inc. on by GoodHouse. In this article, we will summarize the bulls' thesis on PBI. Pitney Bowes Inc.'s share was trading at $11.53 as of August 4th. PBI's trailing and forward P/E were 14.06 and 9.00, respectively according to Yahoo Finance. A busy logistics center filled with trucks and planes, showing the scale of the companies operations. Pitney Bowes (NYSE: PBI) represents a rare opportunity in today's market: a near-monopoly business trading at roughly 5.4x free cash flow, with multiple catalysts to unlock value under the leadership of newly appointed CEO Kurt Wolf. Wolf, the company's largest shareholder and architect of its turnaround following a successful 2023 proxy fight, brings a proven capital allocation track record and has committed to prioritizing shareholder returns. After divesting its loss-making Global E-Commerce segment, Pitney Bowes now operates two core businesses: Presort and SendTech. Presort, which controls approximately 25% market share in mail sortation, generated $671 million in revenue and $217 million in EBITDA over the trailing twelve months, boasting strong margins despite being a low-growth business. The crown jewel is SendTech, a dominant equipment leasing, SaaS, and payments platform with 70% market share, producing $1.25 billion in revenue and $418 million in EBITDA at a 33.5% margin. SendTech's integrated payments arm, PB Bank, amplifies profitability with an 80%+ return on equity, fueled by low-cost customer deposits. The company expects $330–$370 million of free cash flow in 2025, or about $1.93 per share, implying an 18.6% levered FCF yield at current prices. Management plans to execute its full $150 million buyback authorization this year, with further repurchase capacity likely once leverage falls below 3.0x by Q2—earlier than anticipated. This disciplined capital allocation, combined with minimal competitive threats in a highly regulated market, creates significant upside potential. Even modest multiple expansion could drive shares toward $16–$19, while downside risk remains limited given Pitney Bowes' entrenched market position and recurring cash flow profile. Previously, we covered a bullish thesis on Pitney Bowes Inc. (PBI) by Unemployed Value Degen in March 2025, which highlighted activist involvement, restructuring benefits, and ambitious 2025 EBITDA targets. The company's stock price has appreciated by approximately 21% since our coverage. This is because restructuring and divestiture efforts strengthened its financials. GoodHouse shares a similar view but emphasizes Kurt Wolf's appointment as CEO and aggressive buybacks as key catalysts. Pitney Bowes Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held PBI at the end of the first quarter which was 34 in the previous quarter. While we acknowledge the potential of PBI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
11 minutes ago
- Business Wire
Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers and acquirers of Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025 and July 28, 2025, both dates inclusive (the 'Class Period'). Novo Nordisk is a pharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo Nordisk's growth potential. Notably, Novo Nordisk's asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk's branded alternatives. Further, defendants greatly overstated the potential GLP-1 market or otherwise, Novo's capability to penetrate said markets to achieve continued growth. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Novo Nordisk. Investors who want to serve as lead plaintiff for the class must file their motions with the court by September 30, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.